Physician profile
Aws Alameri
NPI 1114423381
$20,151.11
in general payments reported to CMS, 2019-2025
11 companies · $10K in 2025
The $10K reported for 2025 was more than what 93% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $422 · 2024: $9,274 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $13K · Travel and Lodging: $4,868 · Food and Beverage: $2,783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $12,500.00 |
| Travel and Lodging | $4,868.37 |
| Food and Beverage | $2,782.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $16,706.34 | 2024-2025 | General - Therapies, Axios, Overstitch Endoscopic Suturing System |
| Olympus Corporation of The Americas | $1,416.89 | 2024-2025 | Single Use Aspiration Needle Na-U200h |
| Ovesco Endoscopy USA, INC. | $870.19 | 2025 | |
| Abbvie INC. | $249.10 | 2024-2025 | |
| Erbe USA INC | $167.00 | 2025 | Na |
| Fujifilm Healthcare Americas Corporation | $160.00 | 2023-2024 | |
| Medtronic, INC. | $158.76 | 2024 | Barrx, Nexpowder |
| Mallinckrodt Hospital Products INC. | $146.70 | 2023 | Terlivaz |
| Ferring Pharmaceuticals INC. | $121.83 | 2023 | Rebyota |
| Olympus America INC. | $78.36 | 2023 | Endoclot Phs |
| Merit Medical Systems INC | $75.94 | 2024 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aws Alameri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.